Flagship’s Afeyan Sees UK Bet Creating Next Moderna
Flagship Pioneering founder and CEO Noubar Afeyan says the biotech venture firm hopes its new UK investment can grow to as much as £600 million “relatively soon,” as it establishes its first full-scale company-creation operation outside the US. Speaking on Bloomberg’s “The Pulse With Francine Lacqua”, the Moderna co-founder explains why Flagship chose the UK, how AI could accelerate drug discovery and the creation of new biotech companies, and why governments and industry need agreed safeguards…

